Medigene AG

MDG1

DE000A1X3W00

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 09:06:07 10/05/2024 pm IST			5-day change	1st Jan Change
1.44 ^EUR	0.00%		-6.80%	-5.57%

08/05	Medigene Boosts Share Capital Via Rights Offering, Private Placement	MT
02/05	Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 - Targeted T Cell Receptor	CI

MEDIGENE AG : Baader Bank revises his opinion and turns to Neutral

April 12, 2019 at 11:24 am IST

Baader Bank changes its rating and switches from Buy to Neutral. Previously set at EUR 17, the target price is lowered to EUR 11.

Latest news about Medigene AG

Medigene Boosts Share Capital Via Rights Offering, Private Placement	08/05	MT
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 - Targeted T Cell Receptor	02/05	CI
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of A Costimulatory Switch Protein	02/05	CI
Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process	25/04	CI
Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024	08/04	CI
Medigene Gets European Patent for T-Cell Receptor Technology	04/04	MT
Medigene AG Secures European Patent for Its iM-TCR Technology	04/04	CI
Medigene AG Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Transcript : Medigene AG, 2023 Earnings Call, Mar 28, 2024	28/03
Medigene Ag Provides Earnings Guidance for 2024	28/03	CI
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy	04/03	CI
Medigene AG Announces Indication Selection for the Clinical Development of Its Lead 3Rd Generation Tcr-T Therapy Program in Solid Tumors	12/02	CI
Medigene AG Maintains Financial Guidance for the Fiscal Year 2023	21/11	CI
Medigene Presents New Data for MDG 2011, the First TCR in a Novel Kras Library	04/11	CI
Medigene AG Presents First Pre-Clinical Data of Optimal Affinity TCR Targeting mKRAS G12V Combined with a PD1-41BB Costimulatory Switch Protein Showing	23/23/23	CI
Medigene to Present New Pre-Clinical Data for Pipeline TCR-T Therapies At the ESMO Congress 2023	16/23/16	CI
Medigene Expands Intellectual Property Rights for its Costimulatory Switch Proteins to Additional Immune Cell Types	23/23/23	CI
Medigene AG Provides Revenue Guidance for 2023	17/23/17	CI
Transcript : Medigene AG, H1 2023 Earnings Call, Aug 17, 2023	17/23/17
Medigene AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17/23/17	CI
Medigene AG Presents Enhanced Tumor Cell Killing Effects upon Addition of PD1-41BB Switch Receptor to TCR-T Therapies	22/23/22	CI
Transcript : Medigene AG - Special Call	20/23/20
Medigene AG Announces Pipeline Expansion into Neoantigens with Programs Targeting Multiple KRAS Mutations and HLAs	01/23/01	CI
Medigene AG Presents the Web Tool Expitope 3.0 at the 20th Annual Meeting of the Association for Cancer Immunotherapy	04/23/04	CI
Medigene AG Maintains Guidance for the Fiscal Year 2023	03/23/03	CI

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The Company operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.

Sector

Biotechnology & Medical Research

Calendar

15/05/2024 - CIMT Meeting - Abstract Number 3

More about the company

Income Statement Evolution

More financial data

Ratings for Medigene AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.44 EUR

Average target price

2.675 EUR

Spread / Average Target

+85.76%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MEDIGENE AG	-5.57%	38.09M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs

Medigene AG

Equities

MDG1

DE000A1X3W00

Biotechnology & Medical Research

MEDIGENE AG : Baader Bank revises his opinion and turns to Neutral

Latest news about Medigene AG

Chart Medigene AG

Company Profile

Income Statement Evolution

Ratings for Medigene AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs